Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Current Leases: 2023-2024

  • Immunome's Current Leases fell 79.68% to $63,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $63,000, marking a year-over-year decrease of 79.68%. This contributed to the annual value of $63,000 for FY2024, which is 79.68% down from last year.
  • Latest data reveals that Immunome reported Current Leases of $63,000 as of Q4 2024, which was down 75.49% from $257,000 recorded in Q3 2024.
  • Over the past 5 years, Immunome's Current Leases peaked at $310,000 during Q4 2023, and registered a low of $63,000 during Q4 2024.
  • Moreover, its 2-year median value for Current Leases was $257,000 (2024), whereas its average is $210,000.
  • Data for Immunome's Current Leases shows a maximum YoY tumbled of 79.68% (in 2024) over the last 5 years.
  • Over the past 2 years, Immunome's Current Leases (Quarterly) stood at $310,000 in 2023, then plummeted by 79.68% to $63,000 in 2024.
  • Its last three reported values are $63,000 in Q4 2024, $257,000 for Q3 2024, and $310,000 during Q4 2023.